A B S TRA CT The absorption and metabolism of vitamin D3-3H was studied in eight patients with chronic renal failure. Although the intestinal absorption of vitamin D8-3H was normal, the metabolic fate of the vitamin was abnormal as characterized by a twofold increase in fractional turnover rate, an abnormal accumulation of biologically inactive lipid-soluble metabolites, and the urinary excretion of both vitamin D3-3H and biologically inactive metabolites. Neither alterations in watersoluble vitamin D. metabolites nor qualitative abnormalities in protein-binding of vitamin D.
INTRODUCTION
The occurrence of skeletal abnormalities in patients with chronic renal disease (renal osteodystrophy) and the destructive effects of secondary hyperparathyroidism and chronic acidosis on bone in uremia have been well established (1) (2) (3) (4) (5) . Recent observations by Dent, Harper, and Philpot (2) and Stanbury and Lumb (3, 4) suggest that renal osteodystrophy also represents a form of "acquired vitamin D-resistant" bone disease. It seems unlikely that secondary hyperparathyroidism accompanying chronic renal failure causes the vitamin D resistance since, in uremic patients, subtotal parathyroidectomy sufficiently complete to produce hypoparathyroidism fails to alter the resistance to vitamin D (6, 7). The nature of this proposed vitamin D resistance still remains one of the outstanding problems of uremic osteodystrophy. Since vitamin D and its metabolites act primarily by stimulating calcium and phosphate transport in bone, intestine, and kidney (8) , any defect or alteration in its metabolic conversion may contribute to the abnormalities in mineral metabolism often cited in patients with renal osteodystrophy. The latter include: (a) defective intestinal absorption of calcium; (b) defective bone mineralization and metabolism; and (c) resistance to doses of vitamin D which are normally therapeutic. These observations suggest that chronic renal failure with its attendant prolonged uremic state may either result in the interference with the biological activity of vitamin D or alter its metabolism in such a way as to render it biologically inactive.
The recent availability of high specific activity preparations of radioactive vitamin D (8) , as well as technical developments which facilitate the isolation of vitamin D and its metabolites from biological fluids of man (9, 10) , now permit an analysis of vitamin D metabolism in chronic renal failure. Recent developments in hemodialysis and renal transplantation also offer an opportunity to evaluate the effect of temporary amelioration and The Journal of Clinical Investigation Volume 47 1968 (or) complete reversal of the uremic state on the metabolism of vitamin D in man. The present study with radioactive vitamin D. provides evidence that the metabolism and excretion of vitamin D is abnormal in patients with renal disease, and that these abnormalities can be reversed by renal homotransplantation.
METHODS
All subjects were studied on a Clinical Research Center after 14 days of adaptation to diets containing 800 U of vitamin D per day. Eight adults, 21-40 yr of age, with either chronic pyelonephritis or chronic glomerular nephritis (chronic renal disease, CRD) characterized by inulin clearances ranging from 1.7 to 11.4 ml/min, azotemia, hyperphosphatemia, proteinuria (Table I) , and X-ray evidence of generalized skeletal demineralization and (or) osteitis fibrosa, and five normal, healthy adult volunteers of similar ages (29-32 yr) were used for these studies. None of the patients with CRD had previously received pharmacologic doses of vitamin D therapeutically. Two additional patients (J.P. and C.M., Table I) were restudied 1 month after renal homotransplantation. Another patient with CRD (T.D., Table I ) was restudied after 5 consecutive days of continuous 10-hr periods of hemodialysis when blood urea nitrogen, calcium, inorganic phosphate, chloride, sodium, potassium, C02, and arterial pH had reverted toward normal. Finally, to evaluate the effect of proteinuria on the metabolism of vitamin Ds, Ds-3H studies were also employed in a patient with severe proteinuria without uremia (G.S., Table I ilized. Cumulative fecal collections were made in 3-day pools for 6 days, homogenized with water in a Waring blender, and aliquots lyophilized. All fecal collections were initiated and terminated with enemata. Inulin clearance measurements were made according to methods previously described for this laboratory (12) . Determination of total 'H in biological samples. Samples of whole plasma, lyophilized feces, and urine were combusted in a 2 liter Erlenmeyer flask by the procedures described previously (9, 10). After the resulting 'H water vapor was frozen by immersing the flask in a dry ice-acetone bath, 20 ml of liquid scintillation counting solution A was added; 18 ml was then withdrawn and analyzed for radioactivity.
Extraction of radioactivity. Lipid-soluble radioactivity present in plasma, urine, and feces was extracted with methanol and chloroform by the procedure of Bligh and Dyer as previously described (9, 10) . After separation of phases the water-methanol phase was reextracted twice with chloroform. Chloroform extracts were combined and concentrated by evaporation with nitrogen gas and 1-2-ml aliquots added to counting solution B and assayed for radioactivity. 2 ml of the aqueous extract was added to counting solution C and also assayed for radioactivity.
Chromatography. Silica gel G thin-layer chromatography of chloroform-soluble lipid extracts of plasma, urine, and feces were performed in a solvent of 10% acetone in n-hexane (v/v) as previously described (9, 10). After they were dryed, the plates were sprayed with 0.20% KMnO4 in 1% Na2COs to locate the marker vitamin D. The radioactivity was then determined by scraping off successive 0.5 cm segments of silicic acid with a microscopic slide and the scrapings placed in a counting vial containing liquid scintillation counting solution B. The radioactivity migrating with the same Rf as the stable vitamin D markers was labeled "radioactive vitamin D3." The radioactivity in the "vitamin D3 band" was calculated either as a percentage of the administered dose or as a percentage of the total radioactivity in the combusted samples.
Concentrated chloroform extracts of 24-, 48-, and 72-hr plasma samples and of cumulative 3-day urine and 6-day fecal samples were redissolved in Skellysolve B 1 (a petroleum fraction boiling at 65-670C) for application to multibore silicic acid columns. The columns and elution gradients used have been previously described (9, 10). 10-ml fractions from the columns were dried in a stream of air and redissolved in counting solution B for detection of radioactivity.
Electrophoresis. Electrophoresis of serum and urine was conducted according to a modification of previously published starch-block electrophoretic techniques (13 prepared polyvinyl blocks (25 X 38 X 1.5 cm) at 4'C with barbital buffer at pH 8.6. With a constant power source of 300 v and 50 ma, a 35-cm migration was usually obtained in 45-50 hr. The polyvinyl block was then divided into 1 cm strips which were placed in individual centrifuge tubes and extracted with 5 ml of cold 0.9% sodium chloride. The contents of each tube were centrifuged and the supernatant removed. The polyvinyl residue was then reextracted twice with 3-ml portions of cold 0.9%o sodium chloride, the extracts pooled, and aliquots assayed for protein by measurements of optical density at 280 m/A and for radioactivity by liquid scintillation with counting solution C. In selected instances aliquots of the saline extracts of the polyvinyl residue were condensed by negative pressure ultrafiltration and the nature of the proteins migrating with the radioactive peak in the polyvinyl blocks examined by immunoelectrophoretic techniques according to conventional methodology (13) .
Measurement of radioactivity. Counting solution A was used to measure the radioactivity of combusted samples, urine, and feces; the solution consisted of 40 mg of dimethyl-POPOP (1,4-bis [2,5-phenyloxazoly]) benzene, 4 .0 g of PPO (2,5-diphenyloxazole), 200 ml of absolute ethanol, and 800 ml of toluene. Counting solution B, used to measure the tritium content of samples containing organic solvents, consisted only of 3.0 g of PPO and 100 mg of dimethyl-POPOP per liter of toluene. Counting solution C, used to measure tritium in aqueous extracts, was prepared according to the method of Bray (14) . Radioactivity was detected with a Packard Tri-Carb liquid scintillation counter model 3000, equipped with external standardization for determination of counting efficiency.
Bioassay. Various pooled fractions obtained from silicic acid column chromatography of lipid extracts of plasma, fecal, and urine samples were concentrated to dryness in a flash evaporator or by a stream of nitrogen and then dissolved in diethyl ether. 10-ml samples of the ether solution were evaporated on the diet of rachitic rats used for the assay. The vitamin D antirachitic biological assays were subsequently performed according to official USP procedures (15). Silicic acid column fractions were also bioassayed for intestinal calcium transport activity with oxygen-dependent accumulation of 'Ca by duodenal slices obtained from rachitic rats as described by Schachter 
RESULTS
Disappearance and metabolic fate of vitamin D8 in plasma. After the oral dose of D,-'H, plasma D3-3H rose gradually, attaining peak levels within 8-9 hr in all subjects and decreasing exponentially Vitamin D3-3H Metabolism in Chronic Renal Failure thereafter for the remainder of the 6 day study. As noted in Table II , peak plasma D3-3H levels were in each instance lower than normal in patients with CRD. The mean + SE plasma D5-5H half-times for normal and CRD subjects were 27.8 + 1.0 and 13.2 ± 1.1 hr respectively. This difference was highly significant with P < 0.001. The plasma D5-3H half-time in the patient with the nephrotic syndrome (G.S., Table I) Comparative analysis of total radioactivity in whole plasma and chloroform-soluble plasma extracts thereof in both normal and CRD subjects were similar with over 97%o of the plasma radioactivity in the chloroform-soluble phase in each instance.
The results of silicic acid chromatography of chloroform extracts obtained from 48-hr plasma samples in normal and CRD subjects are summarized in Table III . In each instance four fractions were clearly separated. The material in peak 3 has been isolated previously from human plasma after D5-3H administration and identified as unaltered vitamin D. with potent antirachitic and intestinal biological activity (9) . Peak 4, although unidentified structurally, has also been isolated from human plasma and shown to possess antirachitic activity (9) , as well as a remarkable ability to restore active calcium transport mechanisms in the duodenal slices of rachitic rats (17) . Since peak 4 is as biologically active as the parent vitamin in healing experimental rickets in rats and more potent than vitamin D3 in stimulating the intestinal transport of calcium (17) , this material may represent the metabolically active form of the vitamin. Peak 5 is still unidentified but, as shown in Table IV , it is biologically inert. Peak 2 has never been found in large amounts in animals or human subjects and is probably of limited biological significance. Its structure is presently unknown but, by means of saponification and cochromatography, it has been shown to be different from previtamin D and 5,6-trans-vitamin D (8) . Although 57.7 ± 3.2%o of the chromatographed lipid-soluble material in 48-hr plasma samples was normally present in peak 3 (Table III) , only 21.6 ± 4.6%o of the chloroform-soluble material could be identified as unaltered vitamin D in CRD subjects. At 48 hr, 38.3 ± 3.1 and 1.5 ± 0.6%o of the chromatographed radioactivity was normally distributed between peaks 4 and 5 respectively. The metabolites which chromatographed as peak 4 and peak 5 were significantly increased in CRD subjects averaging 65.8 and 10.9%o of the chromatographed chloroform-soluble radioactivity respectively. As illustrated in a normal subject in Fig. 1 and a CRD subject in Fig. 2 , the abnormal distribution of plasma chloroform-soluble radioactivity noted at 48 hr was also present at. 24 hr and intensified at 72 hr after the oral administration of D3-3H. As noted in Table IV and Fig. 3 , unlike material which chromatographed as peak 4 in normal subjects, the peak 4 "metabolite" isolated from the plasma of CRD patients had limited biological activity on bone and intestine when assayed in identical concentrations as measured by radioactivity (disintegrations per minute)-vitamin D3 equivalents. The decreased biological potency of peak 4 substance extracted from the plasma of CRD subjects suggested that the substance was not homogeneous and contained more than one component with varied biological potencies. The material in peak 4 isolated from the uremic patients was subjected to acid and alkaline hydrolysis, 18-glucuronidase hydrolysis, and saponification with 10% KOH in methanol. After these hydrolytic and saponification procedures the respective reaction mixtures were extracted with ether or chloroform and rechromatographed on multibore silicic acid columns as described above. Neither the hydrolytic nor the saponification procedures resulted in the liberation of free D3-3H, a finding which suggests that the bJiologically inactive components of peak 4 in uremic plasma were not merely conjugates of All fractions were bioassayed by the line test technique (15). The amount of each fraction applied to the diet of rachitic rats was estimated on the basis of the specific activity of the parent vitamin D3-3H: 242,000 dpm = 1 Mug.
vitamin D5. Ultrafiltrates 4 of sera obtained from normal and uremic patients 48 hr after oral D5-3H administration were also extracted according to the procedures of Bligh and Dyer as previously published (9) . The chloroform extracts obtained were chromatographed on multibore silicic acid columns as outlined above. Plasma ultrafiltrates from both normal and uremic sera were found to be free of any substance migrating as peak 3 or peak 4, whereas peak 5 concentrations were appreciable in both instances. When compared to normal subjects, the plasma of CRD patients contained, on the average, seven times the amount of material which chromatographed as peak 5 (Table III) . As illustrated in Table IV Table III ).
Distribution of radioactivity and protein after electrophoresis. Electrophoretic patterns of the serum in normal and uremic subjects are shown in Fig. 4 . In each instance four definite protein peaks were separated. During polyvinyl-block electrophoresis radioactivity migrated in two separate peaks which, in both uremic and normal plasma, coincided with the large rapidly moving peak D and a smaller less rapidly moving peak C (Fig. 4) . Immunoelectrophoresis showed the presence of albumin in peak D and a combination of albumin, a 1-and a 2-globulins in peak C. As illustrated for D.K. in Fig. 5 , radioactivity distribution patterns in the plasma and urine of patients with renal disease and proteinuria were remarkably similar. Saline extracts of polyvinyl strips containing the radioactivity of normal and uremic plasma and that of uremic urine were homogenized with methanol and chloroform by the Bligh and Dyer procedures described above. The chloroform-soluble radioactivity was applied to multibore silicic acid columns and chromatographed using the same elution gradient system as described above for whole plasma and urine. In each instance the chloroform-soluble radioactivity of the polyvinyl strips was composed of material which migrated as peak 3 and peak 4. Urinary excretion. As noted in Table V , the mean cumulative urinary excretion of radioactivity for the 72-hr period after the oral D3-3H in five control subjects was 1.69% of the administered dose (range 1.25-2.00). As reported previously in studies describing the fate of an intravenous dose of D3-8H (9), urinary radioactivity in the five normal subjects was mainly water-soluble with an average of 8.7% of the radioactivity soluble in chloroform. In these same normal subjects free vitamin D3 was also conspicuously absent from urine, and the chloroform-soluble radioactivity consisted entirely of the highly polar inactive peak 5 metabolite in each case (Table V) The amount of each compound tested was estimated on the basis of the specific activity of the parent D3-8H: 242,000 dpm = 1 ,ug. Duodenal slices from vitamin D-depleted rats were tested using the experimental methods described by Schachter and coworkers (16) (Table VI) is consistent with prevailing opinions (1, 3) and other unpublished experience from this laboratory documenting the failure of parenteral vitamin D therapy to promote bone healing in renal osteodystrophy when oral therapy has proved ineffectual. The isolated peak 4 metabolite rapidly appears in the plasma of human subjects as vitamin D3 is metabolized (Fig. 1) . Moreover, peak 4 is normally much more efficient than the parent vitamin D in inducing calcium transport by the intestine (Fig. 3) , is biologically active in promoting healing of rachitic bone (Table IV) , and is repeatedly found in the blood of normal human subjects (9, 10), patients with familial vitamin D-resistant rickets (10) , and in the tissues of rachitic chicks given vitamin D3-3H (8) . (23) (24) (25) and man (26) (27) . There is general agreement that the vitamin and its metabolite(s) are bound to albumin, a-globulins, and lipoproteins in stable and nonultrafilterable forms. These observations combined with reports of Schrade, B6hle, and Becker (28) and Klahr, Tripathy, and Bolanos (29) , demonstrating lipiduria and lipoproteinuria in patients with chronic renal disease as well as other studies revealing abnormal protein synthesis in azotemic patients (30) and low molecular weight (a-globulin) proteinuria in chronic renal disease (31) , led to a qualitative electrophoretic analysis of plasma and urinary proteins in subjects with CRD after D8-8H administration. As noted in Fig.  4 , the plasma radioactivity (which proved to be comprised of peak 3 and peak 4) migrated in both normal and CRD subjects with proteins identified immunologically as albumin and a-globulins. Moreover, as illustrated for D.K. in Fig. 5 , plasma and urinary protein-radioactivity relationships were similar in the same uremic individuals. These findings collectively suggest that the abnormal urinary excretion of vitamin D3 and peak 4 observed in CRD subjects was due primarily to the associated proteinuria.
It is our present opinion that the proteinuria and associated renal "leak" of biologically active substances contained in peak 3 and peak 4, albeit characteristic of chronic renal failure, cannot account for the observed rapid disappearance of D3-8H from the plasma of these patients. Identical D8-3H studies performed in G.S. (Table I) , a patient with the nephrotic syndrome without uremia, but excreting 8.0 g of protein per day, revealed a normal plasma D8-3H half-time of 29.0 hr and a normal plasma distribution of vitamin D8-3H and its metabolites at 24, 48, and 72 hr (Table III) despite an obvious urinary loss of vitamin D3 (Table V) . In this case, electrophoretic analysis of plasma and urine also revealed peak 3 and peak 4 migrating with both albumin and the lower molecular weight a-globulins. This isolated observation suggests that the biochemical derangements associated with uremia and prolonged renal insufficiency may be necessary prerequisites for the induction of vitamin D "resistance."
Many of the abnormalities present in patients with chronic renal disease such as anemia (32) , hypertension (33) , glucose intolerance (34) , thrombocytopenia (35) , encephalopathy (36) , and polyneuropathy (37) (33, 38) . These observations are consistent with our findings that hemodialysis (T.D., Tables I, II , III, V) in contrast to homotransplantation (J. P. and C.M., Tables I, II, III, V) was ineffectual in altering the deranged metabolism of vitamin D,.
Animal evidence. indicates that the liver is the site of the maximum concentration of D8-3H after its oral or intravenous administration (39) . Other studies reveal that absorbed vitamin D8-8H is taken up by hepatic cells and excreted into bile (9) . Thus, the liver appears to be an obvious site for the metabolic transformation of vitamin D,.
Schachter, Kowarski, and Finkelstein have also demonstrated that, in the rat, vitamin D acts directly on the small intestine without previous inactivation in another organ (40) . Since, after an intravenous dose of vitamin D3-3H, over 80%o of the intestinal radioactivity represents the biologically active peak 4 metabolite (41), the metabolism and subsequent transformation of vitamin D by the intestine may also be significant. The observed rapid turnover of vitamin D8 in patients Vitamin D3-3H Metabolism in Chronic Renal Failure 
